middle.news

Telix Secures UK Approval for Illuccix, Boosting Prostate Cancer Imaging Access

8:28am on Monday 2nd of June, 2025 AEST Biotechnology
Read Story

Telix Secures UK Approval for Illuccix, Boosting Prostate Cancer Imaging Access

8:28am on Monday 2nd of June, 2025 AEST
Key Points
  • UK MHRA approves Illuccix for prostate cancer PSMA-PET imaging
  • Illuccix addresses critical supply shortages in UK and Europe
  • Local gallium-68 generator production enables flexible, rapid imaging
  • Exclusive UK distribution partnership established with Xiel Limited
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE